» Articles » PMID: 7988457

Two Receptors for Vasoactive Intestinal Polypeptide with Similar Specificity and Complementary Distributions

Overview
Journal Endocrinology
Specialty Endocrinology
Date 1994 Dec 1
PMID 7988457
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Vasoactive intestinal polypeptide (VIP) has a variety of physiological effects. Pharmacological evidence suggesting that VIP acts via multiple receptors has been confirmed by the cloning of two VIP receptors (VIP1 and VIP2) with very different amino acid sequences. At both the VIP1 and the VIP2 receptor VIP, PHI, PACAP38, and PACAP27 have similar potency to each other. Only the VIP1 receptor is activated by secretin. The messenger RNAs (mRNAs) for the two receptors have completely different distributions as mapped by in situ hybridization histochemistry. VIP1 receptor mRNA is predominantly found in the lung, small intestine, thymus, and within the brain in the cerebral cortex and hippocampus. VIP2 receptor mRNA is present in a number of areas where VIP acts but VIP1 receptor mRNA is not present, including the stomach and testes. In the CNS VIP2 receptor mRNA is exclusively present in areas associated with neuroendocrine function, including several hypothalamic nuclei. In the periphery, it is also present in the pituitary and in pancreatic islets.

Citing Articles

CamKIIα and VPAC1 Expressions in the Caudal Trigeminal Nucleus of Rats After Systemic Nitroglycerin Treatment: Interaction with Anandamide.

Nagy-Grocz G, Spekker E, Kortesi T, Laborc K, Bohar Z, Fejes-Szabo A Life (Basel). 2025; 15(2).

PMID: 40003563 PMC: 11856001. DOI: 10.3390/life15020155.


Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine.

Ashina H, Christensen R, Hay D, Pradhan A, Hoffmann J, Reglodi D Nat Rev Neurol. 2024; 20(11):660-670.

PMID: 39256637 DOI: 10.1038/s41582-024-01011-4.


PACAP regulates VPAC1 expression, inflammatory processes and lipid homeostasis in M1- and M2-macrophages.

Witzel R, Block A, Pollmann S, Oetzel L, Fleck F, Bonaterra G Front Cardiovasc Med. 2023; 10:1264901.

PMID: 37900572 PMC: 10611464. DOI: 10.3389/fcvm.2023.1264901.


PACAP and VIP Neuropeptides' and Receptors' Effects on Appetite, Satiety and Metabolism.

Vu J, Luong L, Sanford D, Oh S, Kuc A, Pisegna R Biology (Basel). 2023; 12(7).

PMID: 37508442 PMC: 10376325. DOI: 10.3390/biology12071013.


Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Lu J, Piper S, Zhao P, Miller L, Wootten D, Sexton P Int J Mol Sci. 2022; 23(15).

PMID: 35897648 PMC: 9331257. DOI: 10.3390/ijms23158069.